Friday, December 8, 2017

1:05 PM-2:25 PM Scientific Workshop  
Location: Georgia World Congress Center, Bldg. B, Level 4, B404

New Findings from Population Studies of B-Cell Lymphoma and Leukemia  
Jeffrey Switchenko, PhD

2:25 PM-2:35 PM Scientific Workshop  
Location: Georgia World Congress Center, Bldg. B, Level 4, B404

Next Steps for B-Cell Neoplasms Epidemiology: Towards Translation  
Jeffrey Switchenko, PhD (panelist)

5:10 PM-5:55 PM Scientific Workshop  
Location: Georgia World Congress Center, Bldg. B, Level 2, B211-B212

Point-Counter Point: Prophylactic Transplantation for Leukemia Predisposition Syndromes  
Christopher Porter, MD

Saturday, December 9, 2017

7:30 AM-9:00 AM Scientific Program Presentation  
Location: Georgia World Congress Center, Bldg. C, Level 3, Georgia BR 1-3

Protein Homeostasis: A Key Target in Myeloma  
Number SCI-8 | Lawrence Boise, PhD

7:30 AM-9:00 AM Scientific Program Presentation  
Location: Georgia World Congress Center, Bldg. B, Level 2, B206

Thrombosis-on-a-Chip: A New Way to Model a Complex Process  
Number SCI-10 | Wilbur Lam, PhD

9:30 AM-11:00 AM Scientific Program Presentation  
Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 1-2

T-Cell Memory and Exhaustion  
Number SCI-34 | Rafi Ahmed, PhD

11:15 AM-12:15 PM Career Development Session  
Location: Omni Hotel at CNN Center, International Ballroom F North Tower M2

Medical Educators in Hematology  
Presenter: Kristi Blum, MD

4:00 PM-5:30 PM Scientific Program Presentation  
Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 3-4

Protein Homeostasis: A Key Target in Myeloma  
Number SCI-8 | Lawrence Boise, PhD
5:30 PM-7:30 PM Abstracts
Location: Georgia World Congress Center, Bldg. A, Level 1, Hall A2

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study
Abstract 1869 | Sagar Lonial, MD

Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients
Abstract 1822 | Anjay Nooka, MD, MPH

Impact of Post-Transplant Lymphoproliferative Disorder Subtype on Survival
Abstract 1578 | Jean Koff, MD

Hierarchical Differences in Defensin Gene Expression in Plasmacytoid Dendritic Cells and Progenitor Cells from Five Different Hematopoietic Stem Cell Transplant Graft Types
Abstract 1924 | Cynthia Giver, PhD

High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations
Abstract 1780 | Benjamin Barwick, PhD

Efficacy of Early Post-Transplant Vaccination Using a Prime and Boost Strategy Is Independent of a Prior History of GvHD: Results from BMT CTN 0201
Abstract 1972 | Edmund K. Waller, MD, PhD

Sunday, December 10, 2017

7:30 AM-9:00 AM Scientific Program Presentation
Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B211-B212

Thrombosis-on-a-Chip: A New Way to Model a Complex Process
Number SCI-10 | Wilbur Lam, PhD

9:30 AM-11:00 AM Scientific Program Presentation
Location: Georgia World Congress Center, Bldg. B, Level 5, Murphy BR 1-2

T-Cell Memory and Exhaustion
Number SCI-34 | Rafi Ahmed, PhD

11:15 AM-12:15 PM Training Didactic Session
Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B211-B212

Time Management and Balance: Adult/ Clinical
Presenter: Jean Koff, MD

2:00 PM-3:00 PM Oral Presentation
Location: Georgia World Congress Center, Bldg. B, Level 2, Hall B207-B208

HLA-DRB1-Peptide Binding Prediction and Risk of Inhibitor Development in Non-Severe Hemophilia a
Abstract 177 | Session 322 | Christine Kempton, MD, MSc
6:00 PM-8:00 PM Abstracts
Location: Georgia World Congress Center, Bldg. A, Level 1, Hall A2

Optimization of Ex Vivo Activation and Expansion of T Cells for Therapy of Lymphoma Via Antagonism of PI3K δ and Vasoactive Intestinal Peptide Signaling
Abstract 3195 | Edmund K. Waller, MD, PhD

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab
Abstract 2771 | Christopher R. Flowers, MD, MS

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma
Abstract 3131 | Jonathan Kaufman, MD

A B-Cell like Phenotype Is Associated with Sensitivity to Venetoclax in Multiple Myeloma
Abstract 3073 | Vikas Gupta, MD, PhD

Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays
Abstract 3056 | Shannon Matulis, PhD

Evaluation of Efficacy Outcomes Among Relapsed/Refractory Multiple Myeloma Treated Patients in a Real-World Setting
Abstract 3093 | Ajay Nooka, MD, MPH

Comparison of Overall Survival Associated with Lenalidomide + Dexamethasone and Bortezomib + Dexamethasone Among Relapsed/Refractory Multiple Myeloma Patients: A Matched Analysis of Real World and Clinical Trial Populations
Abstract 3094 | Ajay Nooka, MD, MPH

Monday, December 11, 2017

10:30 AM-12:00 PM Oral Presentation
Location: Georgia World Congress Center, Bldg. A, Level 4, Marcus Auditorium

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study
Abstract 650 | Session 624 | Jonathon Cohen, MD, MS